'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed...
'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed...
默沙东与伊克力西斯合作，在肾癌中测试Zanzalintinib与Welireg联用，保持激酶抑制剂期权开放；合作引发关于默沙东正在进行的与乐普瑞、Litespark-011试验完成日期延迟的疑问...
'Merck Keeps Kinase Inhibitor Options Open As It Partners With Exelixis To Test Zanzalintinib Alongside Welireg In Renal Cancer; Collaboration Raises Questions About Merck's Ongoing Renal Trials With Lenvima, Litespark-011 Trial Completion Is Delayed To 2026; Companies To Co-Fund Phase 1/2 Trial With Merck Sponsoring Two Phase 3 Studies; Merck To Supply Keytruda For Exelixis-Sponsored Head And Neck Cancer Trial' - Oncology Pipeline
默沙东保持激酶抑制剂期权开放，与伊克力西斯合作在肾癌中测试Zanzalintinib和Welireg联合使用；合作引起了关于默沙东正在进行中的利普罗的肾癌试验和Litespark-011试验完成推迟至2026年的疑问；两家公司将共同资助1/2期试验，默沙东赞助两项第三阶段研究；默沙东将为伊克力西斯赞助的头颈癌试验提供Keytruda。- 肿瘤学管道
资讯热榜
更新时间